Results 1 to 10 of about 16,909 (214)

Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator

Molecules, 2021
Deferoxamine B is an outstanding molecule which has been widely studied in the past decade for its ability to bind iron and many other metal ions.
Denise Bellotti, Maurizio Remelli, Remelli Maurizio   +2 more
exaly   +4 more sources

Development of Deferoxamine‐Functionalized Cyclodextrin Polymer for Targeted Iron Chelation [PDF]

ChemistryOpen
Polymeric systems are used in clinical settings to bind small molecules and ions. They show advantages in pharmacokinetics and reduced side effects compared to low‐molecular‐weight agents.
Roberta Panebianco, Maurizio Viale, Graziella Vecchio   +2 more
doaj   +3 more sources

Deferoxamine-Based Materials and Sensors for Fe(III) Detection

Chemosensors, 2022
Deferoxamine (DFO) is a siderophore widely studied for its ability to bind iron(III) strongly. Thanks to its versatility, it is suitable for several clinical and analytical applications, from the recognized iron(III) chelation therapy to the most recent ...
Giancarla Alberti, Camilla Zanoni, Lisa Rita Magnaghi   +2 more
exaly   +4 more sources

Deferoxamine Compensates for Decreases in B Cell Counts and Reduces Mortality in Enterovirus 71-Infected Mice

Marine Drugs, 2014
Enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children under six years of age. No vaccine or antiviral therapy is currently available.
Yajun Yang, Lin Bai, Lianfeng Zhang
exaly   +4 more sources

Deferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression [PDF]

Medicina
Background and Objectives: The objective of this study is to evaluate whether deferoxamine modulates cell biological properties, such as proliferation and wound closure of porcine corneal endothelial cells (CECs) in vitro, and whether the treatment of ...
Barbara Sophie Brunner, Paul Emesz, Nikolaus Luft, Siegfried Georg Priglinger, Andreas Ohlmann, Stefan Kassumeh   +5 more
doaj   +2 more sources

Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis

Neural Regeneration Research, 2019
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair.
Xue Yao, Yan Zhang, Jian Hao, Hui-Quan Duan, Chen-Xi Zhao, Chao Sun, Bo Li, Bao-You Fan, Xu Wang, Wen-Xiang Li, Xuan-Hao Fu, Yong Hu, Chang Liu, Xiao-Hong Kong, Shi-Qing Feng   +14 more
doaj   +2 more sources

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

Journal of Cardiovascular Magnetic Resonance, 2012
Background Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF).
Alpendurada Francisco, Smith Gill C, Carpenter John-Paul, Nair Sunil V, Tanner Mark A, Banya Winston, Dessi Carlo, Galanello Renzo, Walker John, Pennell Dudley J   +9 more
doaj   +2 more sources

Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis

Molecules
Deferoxamine, an iron chelator used to treat diseases caused by excess iron, has had a Food and Drug Administration-approved status for many years. A large number of studies have confirmed that deferoxamine can reduce inflammatory response and promote ...
Haijun Shen, Yane Ma, Yi Qiao, Chun Zhang, Jialing Chen, Ran Zhang   +5 more
doaj   +2 more sources

Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats

Neural Regeneration Research, 2017
Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism for this action remains unknown.
Jian Hao, Bo Li, Hui-quan Duan, Chen-xi Zhao, Yan Zhang, Chao Sun, Bin Pan, Chang Liu, Xiao-hong Kong, Xue Yao, Shi-qing Feng   +10 more
doaj   +2 more sources

Improving adherence with deferoxamine regimen in thalassemia major using education

Iranian South Medical Journal, 2006
Background: Subcutaneous deferoxamine is the first line for management of iron overload in thalassemia major. There is a wide deferoxamine adherence variation in patients with thalassemia major.
Gholamreza Pouladfar, Mandana Moaiedfard
doaj   +1 more source